CYBB and metabolic syndrome: Diabetic rodent models, including those induced by streptozotocin (Stz), exhibit the key features of human pathology, including painful neuropathy [9,10], dyslipidemia [11] and a significant upregulation of Cybb and Bdkrb1 in the spinal cord, which are two specific key molecular targets directly associated with increased hyperglycemia-induced oxidative stress [12,13] and inflammation [8,14–16].